Lead Sponsor

University of Alberta

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•1. Age \> 18 and \< 65 years
•2. Diagnosis of UC for \> 3 months but \< 5 years prior to screening as determined by the investigators
•3. Those with mild to moderate UC
•4. Those who have failed maintenance therapy with stable doses of 5-ASA, azathioprine or 6 mercaptopurine (6-MP) for \> 3 months
•5. Where applicable, those who are taking the following medications must be at a stable dose defined as:
•i) 5-ASA must be at a stable dose for 2 weeks ii) Prednisone up to 20 mg/d must be at a stable dose for 2 weeks iii) Budesonide up to 6 mg/d must be at a stable dose for 2 weeks iv) Azathioprine or 6-MP must be at a stable dose for \> 8 weeks
•6. ability to provide informed consent
•7. evidence of active inflammation

•1. Those whose disease is limited to the rectum (ie. proctitis)
•2. Those with colectomy or diverting ileostomy
•3. Those who are pregnancy or plan to be pregnant during the trial
•4. Those who are breastfeeding or plan to breast feed during the trial
•5. Those who are on or have previously failed a biological agent
•6. Those with an active infection requiring antibiotic therapy
•7. Those with positive stool cultures for known pathogens such as E coli, Salmonella, Shigella, Yersinia, Campylobacter, and Clostridium difficile toxin within 2 weeks of enrollment
•8. Those with positive CMV on colonic tissue biopsy within 2 weeks of screening
•9. Those with allergy to ciprofloxacin and metronidazole
•10. Those with colonic mucosal dysplasia

Related studies

NCT06979336 · Ulcerative Colitis

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

NCT07593352 · IBD and Renal Involement, Chronic Kidney Disease, and more

NCT06100289 · Ulcerative Colitis, Crohn's Disease

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis